RenJi Hospital

Running trials

• Not yet recruiting

  A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

  NCT07632235· Phase 1/2· Source

• Not yet recruiting

  Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer

  NCT07811895· Source

• Recruiting

  Plasma DNA Methylation for Preoperative Classification of Renal Masses

  NCT07874542· Source

• Not yet recruiting

  The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

  NCT07678645· Phase 2· Source

• Recruiting

  Biochemical Response and Clinical Outcomes in Patients With PBC

  NCT07449793· Source

• Recruiting

  Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

  NCT07366528· Phase 3· Source

• Recruiting

  Feasibility Study of Diaphragm Synchronized Pacing (DSP) Via the Left Inferior Phrenic Vein (LIPV) Approach

  NCT07392749· Source

• Recruiting

  Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer

  NCT07187635· Source

• Not yet recruiting

  Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC

  NCT06916117· Phase 2· Source

• Not yet recruiting

  Early Identification and Treatment of Rare Cardiomyopathy Cohorts

  NCT06794710· Source

• Not yet recruiting

  Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

  NCT06621095· Phase 2· Source

• Recruiting

  Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients

  NCT07149935· Source

• Not yet recruiting

  Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

  NCT06531291· Phase 2· Source

• Recruiting

  Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer

  NCT06478225· Source

• Recruiting

  The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction

  NCT06385834· Source

• Recruiting

  Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

  NCT06375473· Source

• Recruiting

  The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure

  NCT06081647· Source

• Recruiting

  Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

  NCT06091124· Phase 2· Source

• Active, not recruiting

  Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

  NCT06577792· Source

• Active, not recruiting

  Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma

  NCT05831891· Phase 2· Source

• Recruiting

  Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

  NCT05595408· Source

• Recruiting

  Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

  NCT06391190· Phase 1/2· Source

• Recruiting

  Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer

  NCT04527861· Source

• Recruiting

  Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial

  NCT05053802· Phase 2· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

  NCT04658862· Phase 3· Source

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Source

• Active, not recruiting

  Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

  NCT04126525· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer4 recruiting
• Bladder cancer3 recruiting
• Gastric and esophageal cancer3 recruiting
• Cervical cancer2 recruiting
• Colorectal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Primary biliary cholangitis2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Coronary artery disease1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Pulmonary arterial hypertension1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Source

• Completed

  Construction of Clinical Diagnostic Model for Pulmonary Hypertension

  NCT06979011· Source

• Completed

  Validation of the Reliability and Validity of the New Endoscopic Scoring System for Ulcerative Colitis (CAT-DESIRE Score) and Verification of Its Clinical Practicability

  NCT07608198· Source

• Completed

  A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma

  NCT06656039· Source

• Completed

  Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

  NCT05861128· Phase 3· Source

• Completed

  Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

  NCT05861102· Phase 3· Source

• Completed

  18F-PBR06/Total Body PET Imaging in Patients With STEMI

  NCT05269446· Source

• Completed

  AccuIMR Predicts Microvascular Obstruction and Infarct Size in STEMI Patients

  NCT06947564· Source